News from gw pharmaceuticals plc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

( AMEX:ANX)

Jan 08, 2014, 23:05 ET

GW Pharmaceuticals plc Announces Pricing of U.S. Follow-On Offering of ADSs Raising $87.9 Million on NASDAQ Global Market

 GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the "Company"), a biopharmaceutical company focused on...

Dec 20, 2013, 09:07 ET

GW Pharmaceuticals Files Registration Statement for Proposed Follow-On Offering

GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the "Company"), a biopharmaceutical company focused on discovering, developing and...

Dec 11, 2013, 02:00 ET

GW Pharmaceuticals plc Announces U.S. Patent Allowance for Use of Cannabinoids in Treating Glioma

 GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the "Company"), a biopharmaceutical company focused on discovering, developing and...

Dec 02, 2013, 02:00 ET

GW Pharmaceuticals to Present at the Piper Jaffray 25th Annual Health Care Conference

GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing...

Nov 27, 2013, 02:00 ET

GW Pharmaceuticals plc Announces Sativex® Regulatory Approval in Switzerland

 GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the "Company"), a biopharmaceutical company focused on discovering, developing and...

Nov 19, 2013, 02:00 ET

GW Pharmaceuticals plc Reports 2013 Q4 and Full Year Financial Results

 GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering,...

Nov 18, 2013, 13:00 ET

GW Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare Conference

 GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering,...

Nov 15, 2013, 02:00 ET

GW Pharmaceuticals Provides Update on Orphan Program in Childhood Epilepsy for Epidiolex®

GW Pharmaceuticals plc (AIM: GWP, Nasdaq: GWPH, "GW") announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug...

Nov 12, 2013, 02:00 ET

GW Pharmaceuticals to Report 2013 Q4 and Full Year Financial Results and Host Conference Call on 19 November, 2013

GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and...

Nov 11, 2013, 02:00 ET

GW Pharmaceuticals Commences Phase 1b/2a Clinical Trial for the Treatment of Glioblastoma Multiforme (GBM)

GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW") a biopharmaceutical company focused on discovering, developing and commercializing novel...

Oct 21, 2013, 02:00 ET

GW Pharmaceuticals Announces Successful Closing of Mutual Recognition Procedure for Sativex® in France

GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the "Company"), a biopharmaceutical company focused on discovering, developing and...

Oct 02, 2013, 08:10 ET

GW Pharmaceuticals Announces New Sativex® Data at ECTRIMS

GW Pharmaceuticals plc (AIM: GWP, Nasdaq: GWPH, "GW") announced that data from new MS spasticity studies (clinical trial data, observational study...

Sep 23, 2013, 06:43 ET

GW Pharmaceuticals Announces Agreement on Sativex® Pricing in Germany

 GW Pharmaceuticals plc (AIM: GWP, Nasdaq: GWPH, "GW") announced today that agreement for a revised mutually-acceptable reimbursement price for...

Sep 20, 2013, 02:00 ET

GW Pharmaceuticals to Present at the 2013 Aegis Capital Healthcare Conference

GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW") announced that Justin Gover, GW's Chief Executive Officer, is scheduled to present a general...

Sep 18, 2013, 02:00 ET

GW Pharmaceuticals Commences Phase 1 Clinical Trial of GWP42006 as a Potential Treatment for Epilepsy

 GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW") announced today it has commenced a Phase 1 clinical trial of product candidate GWP42006...

Aug 14, 2013, 02:00 ET

GW Pharmaceuticals plc Opens an Investigational New Drug Application (IND) in the United States for a Sativex® Phase 3 Clinical Program as a Treatment for Spasticity Due to Multiple Sclerosis

GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW") announced today that it has opened a Phase 3 Investigational New Drug (IND) application with...

Aug 08, 2013, 02:00 ET

GW Pharmaceuticals to Present at the 33rd Annual Canaccord Genuity Growth Conference

 GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering,...

Aug 05, 2013, 02:00 ET

GW Pharmaceuticals plc Reports 2013 Third Quarter Financial Results

GW Pharmaceuticals plc (NASDAQ: GWPH, AIM: GWP, "GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing...

Aug 05, 2013, 02:00 ET

GW Pharmaceuticals Announces Results of MS Spasticity Study Confirming Sativex Has No Long-Term Negative Effect on Cognition

 GW Pharmaceuticals plc (NASDAQ: GWPH, AIM: GWP, "GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering,...

Jul 22, 2013, 02:00 ET

GW Pharmaceuticals Files New Regulatory Application to Expand Sativex® Approval to France

GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the "Company"), a biopharmaceutical company focused on discovering, developing and...